سعر هولديبروتيكت 80/5 مجم 7 اقراص 2022

Fixed-dose combination of amlodipine 5 mg and atorvastatin 80 mg film-coated tablets (Holdiprotect, Memphis, Egypt); pack of 7 tablets.

• Patients for whom treatment with both amlodipine and atorvastatin is appropriate.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Amlodipine component: hypertension, chronic stable angina, vasospastic angina and angiographically documented coronary artery disease.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Atorvastatin component: reduction of cardiovascular risk (myocardial infarction, stroke, revascularisation, angina) in adults at increased risk, and as an adjunct to diet to reduce LDL-C in hyperlipidaemia.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reaction to amlodipine is dose-related oedema; most common adverse reactions to atorvastatin (incidence 5% or more) are nasopharyngitis, arthralgia, diarrhoea, pain in extremity and urinary tract infection.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Acute liver failure or decompensated cirrhosis.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to amlodipine, atorvastatin or any excipient (anaphylaxis, angioneurotic oedema, erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Myopathy and rhabdomyolysis: risk factors include age 65 years or older, uncontrolled hypothyroidism, renal impairment, certain concomitant drugs and higher doses; discontinue if CK is markedly elevated or myopathy is diagnosed or suspected, and report unexplained muscle pain, tenderness or weakness promptly.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Immune-mediated necrotising myopathy (IMNM), an autoimmune myopathy, has been reported rarely with statins; discontinue if suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hepatic dysfunction: transaminase elevations can occur; consider liver enzyme testing before initiation and when clinically indicated.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Moderate and strong CYP3A inhibitorsIncrease amlodipine exposure and may require dose reduction; monitor for hypotension and oedema. Strong inhibitors also raise atorvastatin exposure and myopathy risk.DailyMed (U.S. National Library of Medicine)
• Cyclosporine, tacrolimusAmlodipine may increase their systemic exposure; monitor trough blood levels frequently and adjust the dose when appropriate.DailyMed (U.S. National Library of Medicine)
• Drugs and grapefruit juice that increase the risk of myopathy with atorvastatin (e.g. cyclosporine, gemfibrozil, certain HIV/HCV protease inhibitors, fibrates, niacin, colchicine)Increased risk of myopathy and rhabdomyolysis; follow the label instructions to avoid or limit concomitant use and atorvastatin dose.DailyMed (U.S. National Library of Medicine)

• Discontinue atorvastatin when pregnancy is recognised (alternatively consider the ongoing therapeutic needs of the individual patient); atorvastatin may cause fetal harm based on its mechanism of action, although decades of observational data with statins have not identified a drug-associated risk of major congenital malformations.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Breastfeeding is not recommended during treatment (atorvastatin is present in rat milk and another statin passes into human milk; amlodipine is present in human milk at a median relative infant dose of about 4.2%).International label, same formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.